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lafaxine or sustained release venlafaxine. The results of
this study lend insight useful in making prescribing/for-
mulary decisions for patients with newly diagnosed de-
pression.
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OBJECTIVES: Schizophrenia is a complex and invalidat-
ing disease with a wide range of symptoms and often so-
cial exclusion. Patients’ quality of life is heavily impaired.
The associations between the different symptoms and the
QoL, as well as the possible impact of the patient man-
agement are still not well known. Our objective was to
study the associations between health status, quality of
life, general functioning and patient management in
schizophrenic patients. METHODS: 238 schizophrenic
patients were assessed in a cross sectional study with the
Lehman QoL scale, EuroQoL, SF-36, Calgary Depression
Scale, CGI, GAF and PANSS. At the same time the pa-
tient management was assessed. A progressive approach
using graphical chain models was adopted to determine
the strength of the associations between the different
variables. RESULTS: Depression was strongly associated
with the subjective dimensions of QoL, the utility of Eu-
roQoL and with the mental health sub-score of SF-36.
The schizophrenic symptoms (PANSS) seem to have no
direct impact on the QoL, but only through their associa-
tion to depression and impaired functioning (GAF).
Other factors that seem to have and impact on the QoL
are recent hospitalisation and the type of antipsychotic
drug prescribed, atypical antipsychotics seem more favour-
able compared to typical. CONCLUSIONS: Depression
seems to be the major factor impairing the quality of life
of schizophrenic patients.
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OBJECTIVES: Pharmacotherapy can reduce or prevent
symptom relapse among schizophrenics, thereby provid-
ing long-term benefits. Relapse is common following
noncompliance or discontinuation of antipsychotic medi-
cation, and dissatisfaction with medication may lead to
noncompliance resulting in symptom relapse and in-
creased health care expenditures. We assessed how
schizophrenic patients view the use of antipsychotics.
METHODS: The Drug Attitude Inventory (DAI), com-
prised of 10 “yes/no” questions about efficacy, side ef-
fects and satisfaction, was used to characterize patients’
attitudes and subjective responses to antipsychotic treat-
ment. The DAI was administered to subjects with chronic
or subchronic schizophrenia or schizoaffective disorder in
a forty-week, double-blind, randomized, parallel-group,
flexible-dose study of two regimens of ziprasidone (80 to
120 mg QD or 40 to 80 BID) and one regimen of halo-
peridol (5 to 20 mg daily). A score was calculated as the
sum of the responses to all questionnaire items, and the
subsets of six subjective and four attitudinal questions. A
categorical linear model was used to analyze the marginal
probabilities of favorable responses to the questions. RE-
SULTS: For total, subjective and attitudinal items, DAI
scores at baseline were comparable between treatment
groups. Overall item response significantly favored ziprasi-
done at week 40 (p  0.0016; 7/10 questions showed a
higher percentage of positive responses for ziprasidone,
and the magnitude of differences per question ranged
from 14.2% to 3.7%). This difference was primarily
due to positive responses to the subjective questions (p 
0.0006; 4/6 questions showed a higher percentage of pos-
itive responses for ziprasidone, and the magnitude of dif-
ferences per question ranged from 14.2% to 3.2%).
CONCLUSIONS: Patients in the ziprasidone groups had
a significantly more positive attitude regarding their med-
ication than those in the haloperidol group over 40 weeks
of treatment. These findings have implications for greater
patient compliance with ziprasidone treatment, which
may lead to decreases in relapse rates, hospitalizations,
and other health care resource use.
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OBJECTIVE: Examine which participant level factors
impact the time to switch from first- to second-genera-
tion agents among participants in the Schizophrenia Care
and Assessment Project (SCAP). METHODS: Baseline
data identified participants not receiving second genera-
tion agents (n  520). Accelerated failure time (AFT)
modeling (Weibull distribution error) applied. Number
of years between disease onset and study initiation in-
cluded. Dependent variable: days between study initia-
tion and first switch to second-generation. Right censor-
ing addressed through dichotomous censor variable (1 
switch during window). RESULTS: About one-fourth
(n  133) experienced switch (mean time to switch 
171.08 days). Working hypothesis: persons with higher
side effect and symptom scores and lower functioning
would exhibit shorter time to switch. Persons with higher
side effect scores (AIMS) experienced longer interval until
